

FITC anti-mouse/human Ki-67

Catalog # / Size: 1356055 / 25 µg
1356060 / 100 µg

Clone: 11F6

Isotype: Rat IgG2b, κ

Immunogen: *E. coli* expressed, N-terminal His-Thioredoxin-tagged, partial mKi-67 (1816-2163 aa) recombinant protein.


Reactivity: Human, Mouse

Preparation: The antibody was purified by affinity chromatography and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Workshop Number: HCDM listed

Concentration: 0.5 mg/ml




Con A+IL-2-stimulated (3 days) C57BL/6 mouse splenocytes were fixed and permeabilized with 70% ethanol at -20°C for an hour and stained with Ki-67 (clone 11F6) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).

Applications:

Applications: Intracellular Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes: **ELISA Capture²:** The purified MH9A4 antibody is useful as the capture antibody in a human IL-9 sandwich ELISA assay, when used in conjunction with the biotinylated MH9D1 antibody as the detecting antibody.



Con A+IL-2-stimulated (3 days) C57BL/6 mouse splenocytes were fixed and permeabilized with 70% ethanol at -20°C for an hour and stained with DAPI and Ki-67 (clone 11F6) FITC (left), or rat IgG2b, κ FITC isotype control (right).

Application References: 1. Hase H, *et al.* 2004. *Blood* 6:2257. (IHC)

Description: The nuclear protein Ki-67 was first identified by the monoclonal antibody Ki-67, which was generated by immunizing mice with nuclei of the L428 Hodgkin lymphoma cell line. Ki-67 protein plays an essential role in ribosomal RNA transcription and cell proliferation. Expression of Ki-67 occurs during G1, S, G2, and M phase. While in G0 phase, the Ki-67 protein is not detectable. Ki-67 is strongly expressed in proliferating cells and has been reported as a prognostic marker in various tumors.

**Antigen
References:**

1. Starborg M, et al. 1996. *J. Cell. Sci.* 109:143.
2. Byeon IJ, et al. 2005. *Nat. Struct. Mol. Biol.* 12:987.
3. Yerushalmi R, et al. 2010. *Lancet. Oncol.* 11:174.
4. Beltrami AP, et al. 2001. *N. Engl. J. Med.* 344:1750.
5. Sachsenberg N, et al. 1998. *J. Exp. Med.* 187:1295.
6. Nagy Z, et al. 1997. *Acta. Neuropathol.* 93:294.